Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Solicitation opportunity from Department Of Defense was posted on June 25, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

DoW Neurofibromatosis Exploration-Hypothesis Development Award

Closed
HT942526NFRPEHDAGrant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541715
New
Federal
U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) Organic Industrial Base (OIB) Modernization Commercial Solutions Opening (CSO)
Solicitation # W911PT26SC001
The U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) has issued solicitation W911PT26SC001, a Commercial Solutions Opening (CSO) authorized under the National Defense Authorization Act for Fiscal Year 2026 and DFARS Subpart 212.70. This competitive solicitation is open until September 30, 2027, and is designed to acquire innovative commercial products, technologies, and services to modernize the Army's Organic Industrial Base. The scope focuses on integrating manufacturing resources, linking legacy analogue systems with digital systems, and expanding modeling and simulation to enhance the delivery of materiel solutions. The CSO targets both traditional and non-traditional business entities, including small businesses and foreign-owned firms, provided they maintain an active System for Award Management (SAM) profile and a Unique Entity ID. The acquisition process follows a multi-phased approach consisting of a written solution brief, an optional presentation or pitch, and a final Request for Commercial Solution Proposal (CSP). Evaluation is based on responsiveness, technical merit, uniqueness, and price reasonableness. Successful responses may result in fixed-price contracts awarded under FAR Part 12 Commercial Item Procedures. Current Areas of Interest (AoIs) include advanced cannon technology, electrical infrastructure improvements at Building 120, chromium facility conversion, automated manufacturing for minor components, automated cooling tower treatments, advanced CNC vertical turning lathes, and advanced tooling for radial forging. Performance is primarily located at Watervliet Arsenal and Benet Laboratories, with a general period of performance not to exceed 12 months unless otherwise specified.
W6QK Acc Wva

POSTED

about 8 hours ago

DEADLINE

in 11 months

AI Contract Overview

Show more

The fiscal year 2026 Neurofibromatosis Research Program Exploration-Hypothesis Development Award (EHDA), solicitation number HT942526NFRPEHDA, is issued by the Defense Health Agency to support innovative, high-risk, and high-gain research into neurofibromatosis. The program seeks projects with well-formulated, testable hypotheses that address critical needs in areas such as NF2- and schwannomatosis-related research, biomarker discovery, data science, non-tumor manifestations, and drug discovery. Approximately 1.28 million dollars is allocated to fund about eight awards, with each award capped at 160,000 dollars for a maximum period of performance of two years. The application process is a two-step requirement involving a pre-application Letter of Intent submitted via eBRAP by September 8, 2026, followed by a full application due by September 22, 2026, via eBRAP or Grants.gov. Evaluation follows a two-tier process: a first-tier peer review for technical merit and a second-tier programmatic review for relevance to FY26 NFRP priorities. Key evaluation factors include personnel expertise, budget appropriateness, the scientific environment, and application clarity. Applicants must maintain active registrations in SAM.gov, eBRAP.org, and Grants.gov, and must disclose all foreign affiliations of key personnel to comply with national security requirements. Final deliverables include technical progress reports following RPPR standards and an award expiration transition plan.

General Info

DHA funds eight neurofibromatosis research awards up to 160,000 dollars over two years.

Documents

1

FY26 Neurofibromatosis Research Program Exploration-Hypothesis Development Award

PDF, High priority: read this firstprogram-announcement
High

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseClosed
Posted

Solicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Health Agency Contracting Activity - Dhaca
Contacts1 person available
OfficeUSA

Full Description

Show more

Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Exploration-Hypothesis Development Award (EHDA) supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in neurofibromatosis (NF) research. Studies supported by this award mechanism should lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design.


Distinctive Features:

• Innovation: The proposed research project should be innovative. Innovative research may introduce a novel paradigm, challenge existing paradigms, examine existing problems from novel perspectives, or exhibit other highly creative qualities.

• Preliminary Data: Preliminary and/or published data is encouraged but not required.

More opportunities from Department Of Defense → Defense Health Agency Contracting Activity - Dhaca

Same awarding agency

NAICS: 541715
Grant
DoW Breast Cancer, Breakthrough Award Levels 1 and 2
Solicitation # HT942526BCRPBTA122
The Defense Health Agency Contracting Activity is soliciting applications for the Fiscal Year 2026 Breast Cancer Research Program Breakthrough Award Levels 1 and 2 under solicitation HT942526BCRPBTA122. This program aims to fund high-impact research capable of producing breakthroughs in breast cancer treatment and understanding. Funding Level 1 supports early-stage, high-risk, high-reward research focused on proof of concept without requiring preliminary data, while Funding Level 2 supports research validated by substantial preliminary or published data to facilitate clinical translation. A specialized Population Science Studies option is available under Level 2. The program expects to allot approximately 10.6 million dollars to fund roughly six applications. Eligible applicants may apply as a single Principal Investigator or through a Partnering PI Option. Funding limits vary by level and PI structure, ranging from 750,000 dollars for a single PI at Level 1 up to 3.35 million dollars for partnering PIs conducting Population Science Studies at Level 2. The maximum period of performance is three years, extending to four years for Population Science Studies. Applications are evaluated based on impact, research strategy, and feasibility, with personnel and partnership qualifications also considered. The application process is a two-step submission requiring a pre-application by November 4, 2026, and a full application by November 18, 2026. Required documentation includes a project narrative, statement of work, and various abstracts and statements submitted as specific PDF attachments. Applicant organizations must maintain active registration in SAM.gov and provide a Unique Entity Identifier. Additionally, all key personnel must disclose foreign affiliations, and clinical research proposals must include a Public Health Service Inclusion Enrollment Report.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

about 2 months ago

DEADLINE

in 29 days
View Details
NAICS: 541715
Grant
DoW Breast Cancer, Clinical Research Extension Award
Solicitation # HT942526BCRPCREA2
The FY26 Breast Cancer Research Program Clinical Research Extension Award, solicitation HT942526BCRPCREA2, is a grant opportunity issued by the Defense Health Agency Contracting Activity to support research that extends data collection, follow-up, and analysis of breast cancer clinical studies. The program aims to recover knowledge lost due to early trial termination, limited patient follow-up, or suboptimal data collection, including projects involving deeper molecular analysis of clinical samples. All applications must address at least one FY26 BCRP overarching challenge. The research team is required to include at least two breast cancer consumer advocates. Funding allows for a single Principal Investigator or a partnering arrangement between an Initiating PI and a Partnering PI. The application process is a two-step submission requiring a pre-application Letter of Intent by November 4, 2026, and a full application by November 18, 2026. Pre-applications are submitted via eBRAP, while full applications are submitted through eBRAP for intramural DOW organizations and Grants.gov for extramural organizations. Awards have a maximum period of performance of four years. Evaluation follows a two-tier system consisting of a peer review for technical merit and a programmatic review for relevance. Scored criteria include impact, research strategy and feasibility, partnership (for PPIO applications), and the research sharing plan. Applicants must be registered in SAM.gov with an active status and a Unique Entity Identifier.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

about 2 months ago

DEADLINE

in 29 days
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS